Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Mabpharm Limited ( (HK:2181) ) has shared an update.
Mabpharm Limited announced that all proposed resolutions at its Annual General Meeting held on June 18, 2025, were passed unanimously by shareholders. These resolutions included the re-election of directors, the re-appointment of auditors, and the granting of mandates to the board for share repurchase and issuance. The successful passing of these resolutions reflects strong shareholder support and positions the company for continued strategic growth and operational stability.
More about Mabpharm Limited
Mabpharm Limited is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. The company is listed on the Hong Kong Stock Exchange and focuses on developing and commercializing innovative drugs, particularly in the field of oncology and autoimmune diseases.
Average Trading Volume: 617,320
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.04B
Learn more about 2181 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue